Abstract
Application of amphotericin B in lipid emulsions (AmB/L) reduced membrane toxicity in vitro and decreased amphotericin B-associated toxic side effects in vivo when compared to that of amphotericin B applied in 5% glucose (AmB/G). Therefore, a comparative analysis of the pharmacological parameters of AmB/L and AmB/G was performed. Thirteen patients were analyzed, and nine of these patients received a subsequent treatment with AmB/G and AmB/L. In patients in both treatment groups amphotericin B showed a biphasic elimination from serum, with a prolonged terminal half-life of approximately 27 h. Patients treated with AmB/L showed significantly lower peak concentrations (44.2%; P = 0.008) and correspondingly lower area under the drug concentration-time curve (AUC) values (64.3%; P = 0.015) compared to the values for the same patients treated with AmB/G at a dose range of 0.6 to 1.5 mg/kg of body weight. The enhanced clearance of AmB/L may be due to a faster initial elimination of amphotericin B-lipid aggregates by the reticuloendothelial system. Lower peak concentrations and AUC values in serum and a correspondingly faster deposition of AmB/L in tissues may at least partly explain the lower toxicity of AmB/L. A comparative pharmacokinetic analysis with data for a single patient treated with AmB/L demonstrated that hemodialysis did not significantly affect the disposition of amphotericin B.
Full Text
The Full Text of this article is available as a PDF (197.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bolard J., Legrand P., Heitz F., Cybulska B. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry. 1991 Jun 11;30(23):5707–5715. doi: 10.1021/bi00237a011. [DOI] [PubMed] [Google Scholar]
- Burch P. A., Karp J. E., Merz W. G., Kuhlman J. E., Fishman E. K. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol. 1987 Dec;5(12):1985–1993. doi: 10.1200/JCO.1987.5.12.1985. [DOI] [PubMed] [Google Scholar]
- Butler W. T., Cotlove E. Increased permeability of human erythrocytes induced by amphotericin B. J Infect Dis. 1971 Apr;123(4):341–350. doi: 10.1093/infdis/123.4.341. [DOI] [PubMed] [Google Scholar]
- Caillot D., Casasnovas O., Solary E., Chavanet P., Bonnotte B., Reny G., Entezam F., Lopez J., Bonnin A., Guy H. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother. 1993 Jan;31(1):161–169. doi: 10.1093/jac/31.1.161. [DOI] [PubMed] [Google Scholar]
- Caillot D., Reny G., Solary E., Casasnovas O., Chavanet P., Bonnotte B., Perello L., Dumas M., Entezam F., Guy H. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother. 1994 Mar;33(3):603–613. doi: 10.1093/jac/33.3.603. [DOI] [PubMed] [Google Scholar]
- Chavanet P. Y., Garry I., Charlier N., Caillot D., Kisterman J. P., D'Athis M., Portier H. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ. 1992 Oct 17;305(6859):921–925. doi: 10.1136/bmj.305.6859.921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Feldman H. A., Hamilton J. D., Gutman R. A. Amphotericin B therapy in an anephric patient. Antimicrob Agents Chemother. 1973 Sep;4(3):302–305. doi: 10.1128/aac.4.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gruda I., Dussault N. Effect of the aggregation state of amphotericin B on its interaction with ergosterol. Biochem Cell Biol. 1988 Mar;66(3):177–183. doi: 10.1139/o88-024. [DOI] [PubMed] [Google Scholar]
- Janoff A. S., Boni L. T., Popescu M. C., Minchey S. R., Cullis P. R., Madden T. D., Taraschi T., Gruner S. M., Shyamsunder E., Tate M. W. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A. 1988 Aug;85(16):6122–6126. doi: 10.1073/pnas.85.16.6122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Joly V., Farinotti R., Saint-Julien L., Chéron M., Carbon C., Yeni P. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob Agents Chemother. 1994 Feb;38(2):177–183. doi: 10.1128/aac.38.2.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Khoo S. H., Bond J., Denning D. W. Administering amphotericin B--a practical approach. J Antimicrob Chemother. 1994 Feb;33(2):203–213. doi: 10.1093/jac/33.2.203. [DOI] [PubMed] [Google Scholar]
- Kirsh R., Goldstein R., Tarloff J., Parris D., Hook J., Hanna N., Bugelski P., Poste G. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis. 1988 Nov;158(5):1065–1070. doi: 10.1093/infdis/158.5.1065. [DOI] [PubMed] [Google Scholar]
- Legrand P., Romero E. A., Cohen B. E., Bolard J. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother. 1992 Nov;36(11):2518–2522. doi: 10.1128/aac.36.11.2518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moreau P., Milpied N., Fayette N., Ramée J. F., Harousseau J. L. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother. 1992 Oct;30(4):535–541. doi: 10.1093/jac/30.4.535. [DOI] [PubMed] [Google Scholar]